SEER*Rx Interactive Antineoplastic Drugs Database
SEER is supported by the Surveillance Research Program (SRP) in NCIs Division of Cancer Control and Population Sciences (DCCPS). SRP provides national leadership in the science of cancer surveillance as well as analytical tools and methodological expertise in collecting, analyzing, interpreting, and disseminating reliable population-based statistics.. ...
Adrenocortical Carcinoma Treatment (PDQ®) - NCI
Chemotherapy with mitotane plus streptozotocin or mitotane plus etoposide, doxorubicin, and cisplatin may be effective and has ... Chemotherapy with mitotane plus streptozotocin or mitotane plus etoposide, doxorubicin, and cisplatin, as evidenced by the ...
https://www.cancer.gov/types/vulvar/hp/vulvar-treatment-pdq
In the four studies using 5-FU with either cisplatin or mitomycin, the operability rate after chemoradiation therapy ranged ... In summary, there is evidence that neoadjuvant chemoradiation therapy with 5-FU plus either cisplatin or mitomycin may convert ... Eifel PJ, Morris M, Burke TW, et al.: Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally ... Eifel PJ, Morris M, Burke TW, et al.: Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally ...
CanMED: HCPCS
Cisplatin Platinol, Platinol-AQ. 10 mg. Chemotherapy Alkylating Agent. Platinum Compound. No 1978. Jan. 1, 1984 In Use. ... Cisplatin Platinol, Platinol-AQ. 50 mg. Chemotherapy Alkylating Agent. Platinum Compound. No 1978. Jan. 1, 1982 Dec. 31, 2010 ... Cisplatin Platinol, Platinol-AQ. 10 mg. Chemotherapy Alkylating Agent. Platinum Compound. No 1978. Jan. 1, 2004 Dec. 31, 2005 ...
CanMED: NDC
Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 19, 2012 Dec. 31, 2017 No ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 19, 2012 Dec. 31, 2017 No ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. June 12, 2017 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Oct. 16, 2017 In Use. ...
CanMED: NDC
Cisplatin. Cisplatin. 50.0 mg/50mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. June 1, 2000 In Use. ... Cisplatin. Cisplatin. 100.0 mg/100mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. June 1, 2000 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Dec. 13, 2016 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Dec. 13, 2016 In Use. ...
CanMED: NDC
Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 19, 2012 Dec. 31, 2016 No ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 19, 2012 Dec. 31, 2016 No ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 19, 2012 Dec. 31, 2017 No ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 19, 2012 Dec. 31, 2017 No ...
CanMED: HCPCS
Cisplatin Platinol, Platinol-AQ. 10 mg. Chemotherapy Alkylating Agent. Platinum Compound. No 1978. Jan. 1, 2004 Dec. 31, 2005 ...
CanMED: NDC
Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. June 12, 2017 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Oct. 16, 2017 In Use. ...
CanMED: NDC
Cisplatin. Platinol-AQ. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Jan. 13, 2012 Jan. 13, 2012 In ... Cisplatin. Platinol. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Jan. 13, 2012 Jan. 13, 2012 In ...
CanMED: NDC
Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 3, 2017 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 3, 2017 In Use. ...
CanMED: NDC
Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. July 1, 2023 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. July 1, 2023 In Use. ... CISPLATIN. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Sept. 1, 2023 In Use. ... Cisplatin. CISPLATIN. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Aug. 11, 2023 In Use. ...
CanMED: NDC
cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. April 5, 2019 In Use. ...
CanMED: NDC
Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Dec. 13, 2016 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Dec. 13, 2016 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Jan. 13, 2012 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Jan. 13, 2012 In Use. ...
CanMED: HCPCS
Cisplatin Platinol, Platinol-AQ. 50 mg. Chemotherapy Alkylating Agent. Platinum Compound. No 1978. Jan. 1, 1982 Dec. 31, 2010 ...
CanMED: NDC
Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. July 1, 2023 In Use. ... Cisplatin. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. July 1, 2023 In Use. ... CISplatin. CISplatin. 50.0 mg/50mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. June 6, 2023 In Use. ... CISPLATIN. Cisplatin. 1.0 mg/mL. Chemotherapy Alkylating Agent Platinum Compound. Intravenous. Sept. 1, 2023 In Use. ...
Small Cell Lung Cancer Treatment (PDQ®) - NCI
Kubota K, Hida T, Ishikura S, et al.: Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage ... Lara PN, Natale R, Crowley J, et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive- ... Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small- ... Hanna N, Bunn PA, Langer C, et al.: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in ...
Targeted Treatment for Rare GI Cancers May Extend Survival - NCI
Currently, the first-line therapy for biliary tract cancer is a combination of the chemotherapy drugs cisplatin and gemcitabine ...
Rectal Cancer Treatment (PDQ®) - NCI
... radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy. Int J Radiat Oncol Biol Phys 70 (2): 403-12, 2008. [PUBMED ...
News and Announcements | Office of Cancer Clinical Proteomics Research
Cisplatin, the first platinum-based anti-cancer therapy, was approved by the Food and Drug Administration (FDA) for... ...
Antineoplastons (PDQ®) - NCI
Growth inhibition of one of the cell lines (KIM-1) was observed at low concentration for a mixture of cisplatin (CDDP) and A10 ... but this result was probably caused by the cisplatin, which was effective at concentrations of 0.5 to 2.0 μg/mL when tested ...
Clarifying Timing of Immunotherapy for Advanced Bladder Cancer - NCI
All trial participants had already received chemotherapy-with either cisplatin and gemcitabine (Gemzar) or carboplatin and ... such as cisplatin), the cancer almost always returns rapidly, sometimes within just a few weeks or months, and grows ... gemcitabine, if their health did not allow them to receive cisplatin-and their disease had not worsened during chemotherapy. ...
Yves Pommier, M.D., Ph.D. | Center for Cancer Research
... cisplatin, oxaliplatin, cyclophosphamide, temozolomide) and antimetabolites (cytarabine, gemcitabine, methotrexate) are widely ...
Discovery & Development Services | Developmental Therapeutics Program (DTP)
Cisplatin (cis-platinum) (NSC 119875). 2010. Eribulin (NSC 707389). Sipuleucel-T (NSC 720270). 1977. Carmustine (BCNU) (NSC ...